Abstract
The intronic variant rs4252120 in the plasminogen gene (PLG) is known to be associated with aggressive periodontitis (AgP) and atherosclerosis. Here, we examined the chromosomal region spanning PLG for associations with both chronic periodontitis (CP) and AgP.
Materials and MethodsThe association of PLG candidate rs4252120 was tested in a German case–control sample of 1,419 CP cases using the genotyping assay hCV11225947 and 4,562 controls, genotyped with HumanOmni BeadChips. The German and Dutch sample of AgP cases (N = 851) and controls (N = 6,836) were genotyped with HumanOmni BeadChips. The North American CP sample (N = 2,681 cases, 1,823 controls) was previously genotyped on the Genome‐Wide Human SNP Array 6.0. Genotypes were imputed (software Impute v2), and association tests were performed using an additive genetic model adjusting for sex and smoking.
ResultsRs4252120 was not associated with CP. However, a haplotype block downstream of PLG and not in linkage disequilibrium with rs4252120 (r2 = .08) was associated with both AgP (rs1247559; p = .002, odds ratio [OR] = 1.33) and CP (p = .02, OR = 1.15). That locus was also significantly associated with PLG expression in osteoblasts (p = 6.9 × 10−5).
ConclusionsOur findings support a role of genetic variants in PLG in the aetiology of periodontitis.
Original language | English |
---|---|
Pages (from-to) | 962-970 |
Journal | Journal of Clinical Periodontology |
Volume | 44 |
Issue number | 10 |
DOIs | |
Publication status | Published - 2017 |
Funding
This study was supported by a research grant of the Deutsche Forschungsgemeinschaft DFG (GZ: SCHA 1582/3-1). The Dortmund Health Study (DOGS) is supported by the German Migraine & Headache Society (DMKG) and by unrestricted grants of equal share from Almirall, Astra Zeneca, Berlin Chemie, Boehringer, Boots Health Care, Glaxo-Smith-Kline, Janssen Cilag, McNeil Pharma, MSD Sharp & Dohme, and Pfizer to the University of Muenster (collection of sociodemographic and clinical data). Blood collection in the Dortmund Health Study was carried out through funds from the Institute of Epidemiology and Social Medicine University of Muenster. FOCUS was supported by the Federal Ministry of Education and Research BMBF (FKZ 0315540A). The HNR study is supported by the Heinz Nixdorf Foundation (Germany). Additionally, the study is funded by the German Ministry of Education and Science and the German Research Council (DFG; Project SI 236/8-1, SI236/9-1, ER 155/6-1). The genotyping of the Illumina HumanOmni-1 Quad BeadChips of the HNR subjects was financed by the German Centre for Neurodegenerative Disorders (DZNE), Bonn.
Funders | Funder number |
---|---|
Federal Ministry of Education and Research BMBF | FKZ 0315540A |
German Centre for Neurodegenerative Disorders | |
German Migraine & Headache Society | |
University of Muenster | |
Pfizer | |
Merck Sharp and Dohme | |
Deutsche Forschungsgemeinschaft | SCHA 1582/3-1, ER 155/6-1, SI 236/8-1, SI236/9-1 |
Bundesministerium für Bildung und Forschung | |
Deutsches Zentrum für Neurodegenerative Erkrankungen | |
Deutsche Migräne- und Kopfschmerzgesellschaft e.V. | |
Heinz Nixdorf Stiftung |